Thermo Fisher Scientific’s PPD business has partnered with HealthVerity, a leading real‑world data marketplace, to give its clinical research clients enterprise‑level access to the company’s TaXOnomy® claims dataset, which contains more than 270 million de‑identified patient records.
"This collaboration advances our ability to integrate high‑quality, linked healthcare data into clinical development,” said Krishna Cheriath, vice president, head of clinical research digital and AI, biopharma services, Thermo Fisher Scientific. “By utilizing one of the largest integrated healthcare data ecosystems with our AI‑enabled analytics, we can generate robust real‑world evidence to support our customers across the clinical and post‑approval continuum.”
The partnership aligns with Thermo Fisher’s strategy to become a one‑stop‑shop for biopharma services. By combining PPD’s clinical trial expertise with HealthVerity’s extensive, longitudinal data, sponsors can design trials, identify patient cohorts, and generate real‑world evidence more efficiently, potentially accelerating development timelines and reducing costs.
The move also positions Thermo Fisher to capture a larger share of the growing real‑world evidence market, where regulatory agencies increasingly accept RWE to support drug approvals and label expansions. HealthVerity’s marketplace, which aggregates more than 70 curated data sources, complements Thermo Fisher’s existing analytics platform and strengthens its competitive edge against other CROs such as IQVIA and ICON.
Overall, the collaboration is expected to deepen relationships with existing biopharma clients and attract new sponsors seeking advanced data‑driven solutions, thereby supporting Thermo Fisher’s long‑term revenue growth and reinforcing its leadership in the life‑sciences services sector.
revised_sentiment_rating
}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.